Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 7, 2023 (4 years ago)

Dofetilide Capsules 250 mcg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Dofetilide Capsules 250 mcg (0.25 mg) 60-count bottle, Rx only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA NDC 16729-491-12 UPC 3 16729 49112 9

Affected NDC 16729-0491-12

Compare with the code on your package — it is the most precise check available.

Drug: Dofetilide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dofetilide
NDC 16729-0491
.25 mg/1 Capsule
Oral
Accord Healthcare, Inc. Rx
Recalling firm
Accord Healthcare, Inc.
NDC code
16729-491-12
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0384-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Dofetilide recalls

See all
Class II · Moderate risk

Dofetilide Capsules 500 mcg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-492-12 D-0385-2023
Class II · Moderate risk

Dofetilide Capsules

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-490-12 D-0383-2023
Class II · Moderate risk

Tikosyn (dofetilide)

Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.

Terminated Failed specification Pfizer Inc. NDC 0069-5800-61 D-0292-2015

Other recalls by Accord Healthcare, Inc.

All 2023 recalls